Renal Effects of Combination Phosphodiesterase V Inhibition and Low-Dose B-Type Natriuretic Peptide in Acute Heart Failure: A Randomized Clinical Trial

What Was Tested

This randomized controlled trial paper looks at BNP (Nesiritide).

Cardiorenal dysfunction with impaired cyclic GMP (cGMP) response is common in patients presenting with acute heart failure (HF).

Type V phosphodiesterase (PDEV) is known to be upregulated in HF and may explain the dysfunction of renal response.

Who Took Part

According to the abstract, 67 patients were involved.

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, both men and women.

This open-label study included 67 patients hospitalized with acute HF and renal dysfunction.

How the Study Was Run

The design is described as randomized and open-label.

Because people in this BNP (Nesiritide) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Nothing was hidden in this open-label BNP (Nesiritide) study: the patients and staff both knew the treatment.

The coprimary end points were the percent change in estimated glomerular filtration rate and blood urea nitrogen from baseline to 48 hours.

What Was Measured

Topics PubMed links to this paper include Natriuretic Peptide, Brain, Heart Failure, Cyclic GMP, Phosphodiesterase 5 Inhibitors, Glomerular Filtration Rate, Acute Disease and Sildenafil Citrate.

The authors tagged it with the keywords cyclic nucleotide phosphodiesterases, type 5 and kidney.

What This Means in Plain Language

The paper is a randomized and open-label study of BNP (Nesiritide) in 67 patients.

Results are reported in around 5 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2024 (Circulation. Heart failure), a journal based in United States.

More context: the BNP (Nesiritide) compound page, all human trials.